Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

ClinicalTrials.gov ID: NCT02945579

Public ClinicalTrials.gov record NCT02945579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

Study identification

NCT ID: NCT02945579
Recruitment status: Recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: M.D. Anderson Cancer Center; Other
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

Radiation · Other

Eligibility (public fields only)

Age range: 30 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 19, 2017
Primary completion: Jan 30, 2028
Completion: Jan 30, 2028
Last update posted: Mar 8, 2026

2017 – 2028

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
MD Anderson Cancer Center - Banner	Gilbert	Arizona	85234	Completed
Baptist MD Anderson Cancer Center	Jacksonville	Florida	32207	Recruiting
Queen's Medical Center	Honolulu	Hawaii	96813	Completed
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees	Voorhees Township	New Jersey	08103	Recruiting
Carolinas Medical Center/Levine Cancer Institute	Charlotte	North Carolina	28203	Recruiting
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	Recruiting
M D Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02945579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 8, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02945579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →